RedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma: Net revenues for 2017 totaled $4M, and met our expectations. We expect Redhill to raise capital in anticipation of its announcement of top-line Phase III results for Crohn’s disease, expected in mid-2018; Price target raised to NIS 2.59
BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingBiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15
